Results 51 to 60 of about 225,391 (165)

A Case of Euthyroid Graves’ Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody

Case Reports in Endocrinology, 2018
We report of a case of Graves’ ophthalmopathy presented solely with symptoms of the eyes with normal thyroid function tests and negative immunoreactive TSH receptor autoantibody.
Asami Hotta, Tomohiro Tanaka, Haruka Kato, Shota Kakoi, Yuki Shimizu, Chie Hasegawa, Akiko Hayakawa, Satoshi Yasuda, Kento Ogawa, Shunsuke Ito, Hideomi Ohguchi, Takashi Yagi, Hiroyuki Koyama, Mihoko Kawamura, Kazuhiko Sugitani, Yuichiro Ogura, Takashi Joh, Kenro Imaeda   +17 more
doaj   +1 more source

A Pruritic Predicament: An Unusual Presentation of Graves’ Disease Complicated by Pregnancy

Case Reports in Medicine, Volume 2026, Issue 1, 2026.
Pruritus is a known but uncommon symptom of hyperthyroidism that can be misinterpreted or overlooked in a patient presentation. This is a case report of a 40‐year‐old female who presents with a 3‐month history of severe, worsening pruritus. Further history demonstrated potential signs of hyperthyroidism, and laboratory values demonstrated low TSH ...
Rob Lawless, Evan Smith, Camryn Slone, Thaddeus Salmon, Semonti Nandi   +4 more
wiley   +1 more source

Hypothyroid Graves’ Ophthalmopathy: Report of Two Cases

Endocrinology Research and Practice, 2007
Graves’ disease is an autoimmune disorder of the thyroid gland. Ophthalmopathy is the most common peripheral manifestation of Graves’ disease. It is a very rare condition that a Graves’ patient presents with spontaneous hypothyroidism.
Barış Akıncı, Tevfik Demir, Abdurrahman Çömlekçi   +2 more
doaj   +2 more sources

Lugol’s Iodine as a Key Treatment in Transient Gestational Thyrotoxicosis: A Case Report

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Introduction Transient gestational thyrotoxicosis (TGT) occurs when human chorionic gonadotropin (hCG) directly stimulates the maternal thyroid gland during the first trimester of pregnancy. We report a case of complicated TGT in a young woman who required treatment with Lugol’s solution.
Mariam Mabrouk, Najla Bchir, Dorra El Guiche, Anaam Ben Chehida, Emna Mraihi, Chadia Zouaoui, Haroun Ouertani, Mohammad Shahangir Biswas   +7 more
wiley   +1 more source

Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves′s ophthalmopathy

Indian Journal of Endocrinology and Metabolism, 2013
Pulse methylprednisolone therapy is the recommended therapy for moderate to severe and active ophthalmopathy, but high dose pulse methylprednisolone therapy is marred by the chances of fulminant hepatic failure and the high cost of therapy. Dexamethasone
Rajeev Philip, Sanjay Saran, Manish Gutch, Pushpaltha Agroyia, Rajiv Tyagi, Keshavkumar Gupta   +5 more
doaj   +1 more source

Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development

Taiwan Journal of Ophthalmology, 2020
Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still
Yazhuo Huang, Sijie Fang, Shuo Zhang, Huifang Zhou   +3 more
doaj   +1 more source

Unilateral Graves’ Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Background Tirzepatide is a dual agonist of the glucose‐dependent insulinotropic polypeptide (GIP) receptor and glucagon‐like peptide‐1 (GLP‐1) receptor, demonstrates significant efficacy in lowering blood glucose levels and reducing body weight. Consequently, its use has increased among patients with type 2 diabetes and obesity.
Yusuke Deto, Ryo Hasegawa, Shoya Ino, Satoru Shibata, Kouhei Ohno, Takahito Itoh, Tomoaki Matsumoto, Takayuki Miki, Kalyani Sen   +8 more
wiley   +1 more source

Exploring the Therapeutic Mechanism of Xiehuo Pingtu San in Treating Thyroid Eye Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang, Ruiyan Liu, Xin Shang, Yu Fu, Ying Wang, Shuxun Yan, Suraiya Saleem   +6 more
wiley   +1 more source

Early Low‐Dose Rituximab for Mild‐to‐Moderate Thyroid Eye Disease: A Preliminary Evaluation of Efficacy and Safety

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Thyroid eye disease (TED) is an autoimmune inflammatory condition linked to thyroid dysfunction, which can result in disfigurement and potential vision loss. Recently, immunomodulatory therapies such as rituximab have demonstrated potential benefit in managing TED.
Ming Lu, Luqiang Wang, Xuelian Zhang, Suraiya Saleem   +3 more
wiley   +1 more source

Factors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study

Journal of Ophthalmology, Volume 2026, Issue 1, 2026.
Purpose The conversion rate of ocular myasthenia gravis (OMG) to generalized myasthenia gravis (GMG) lacks definitive predictors. Methods This retrospective cohort study analyzed data collected at Siriraj Hospital between January 2007 and December 2019 to identify factors influencing OMG generalization and the time to conversion. The records of 200 OMG
Wanicha Chuenkongkaew, Niphon Chirapapaisan, Pawimon Chatchutimakorn, Natthapon Rattanathamsakul, Manassawee Joradoln, Pawita Kongthanasomboon, Akarawit Eiamsamarng, Gábor Tóth   +7 more
wiley   +1 more source